ABL Bio Inc. (KOSDAQ:298380)

Revenue by Segment

Financials in millions KRW. Fiscal year is January - December.

Fiscal Year	FY 2023	FY 2022	FY 2021
Period Ending	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Biotechnology (Startups)	65.55B	67.30B	5.33B
Biotechnology (Startups) Growth	-2.61%	1162.19%	-
Total	65.55B	67.30B	5.33B
Total Growth	-2.61%	1162.19%	-

Revenue by Geography

Financials in millions KRW. Fiscal year is January - December.

Fiscal Year	FY 2023	FY 2022	FY 2021
Period Ending	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
South Korea	2.00B	2.38B	483.55M
South Korea Growth	-16.30%	393.11%	-
United States	63.55B	62.32B	4.85B
United States Growth	1.98%	1185.24%	-
China	-	2.60B	-
Total	65.55B	67.30B	5.33B
Total Growth	-2.61%	1162.19%	-

Source: S&P Global Market Intelligence.